Navigation Links
Sales of Antiretroviral Agents Will Drive Substantial Six Percent Annual Growth in the HIV Drug Market Through 2013
Date:5/19/2009

By 2018, Gilead's Quad Will Become the Highest-Selling Antiretroviral in the World's Major Markets, According to a New Report from Decision Resources

WALTHAM, Mass., May 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that sales of antiretroviral agents will drive substantial six percent annual growth in the HIV drug market through 2013 but significant generic erosion of key therapies thereafter will slow annual growth to less than two percent from 2013 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Human Immunodeficiency Virus finds that continued increase in the uptake of Bristol-Myers Squibb/Gilead's Atripla will drive the agent to garner the highest sales of any antiretroviral in 2013. However, from 2013 to 2018, Gilead's Quad will make significant inroads in the HIV market and by 2018 will become the highest-selling antiretroviral drug in the world's major markets, according to the report. Quad will combine favorable safety and efficacy with the dosing convenience of a single daily pill regimen, making it an ideal product for treatment-naive patients.

"The largest commercial opportunities in the HIV market lie in the development of therapies with enhanced convenience, such as co-formulations that minimize the number of pills and frequency of dosing, especially safe and effective therapies that target treatment-naive patients -- the most lucrative segment of the market," said Decision Resources Analyst Jose Avalos, Ph.D. "In addition, agents with reduced long-term toxicities can differentiate themselves in this crowded market."

The report also finds that two novel classes of antiretroviral agents -- the integrase inhibitors and CCR5 antagonists -- have been received with different levels of enthusiasm among inter
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Psychemedics Corporation Announces Sales & Marketing Agreement With Bupa in UK
2. GeckoSystems Reveals Eldercare Capable Personal Robot Sales Forecasts
3. Herbal Supplement Sales Increase in US in 2008
4. U.S. Mobile Robot Co. Reveals Pacific Rim Sales Forecasts
5. Growth in Drug Sales of the Top 10 Pharmaceutical Companies Slowed to its Lowest Level in Years in 2008
6. OrthoSynetics Selects Landslides Sales P3 System as its Corporate Sales System
7. RBC Life Sciences North American Nutritional Supplements and Medical Products Sales Increased, Year Over Year, During the First Quarter of 2009
8. Milestone Scientific Reports Strong Sales Growth in First Quarter 2009 Results
9. Woodward Labs Reports Sales Spike for HandClens(R) Alcohol-Free Hand Sanitizer During Swine Flu Epidemic
10. Driven by Sales of Enbrel, Remicade and Humira, spondyloarthropathies Drug Market Grew to Nearly $2 Billion in 2008
11. Archi-Tech InView Now Supports Managed Care Data, Offering an Interactive Dashboard for On-Demand Sales Planning and Reporting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)... Trust Inc. (NYSE: CRE ) ("Care" or the ... dividend of $0.17 per share of common stock. The dividend ... on December 14, 2009. ,, About Care ... estate investment and finance company investing in healthcare-related real estate and ...
(Date:12/4/2009)... Medithrive, Inc. has won the Patient,s Choice Award ... by popular vote conducted by the online website, ... SF Bay community has selected Medithrive as the preeminent ... rapid rise and popularity of Medithrive confirms the obvious: ...
(Date:12/4/2009)... Dec. 4 The American Association of Homes and Services ... the Community Living and Supportive Services (CLASS) provisions remain ... are essential for providing support to elders, people with disabilities ... pass a health care reform bill that will make it ...
(Date:12/4/2009)... The large, two-day free health clinic sponsored by the ... Wednesday and Thursday is not just for the sick but ... a doctor recently. All participants in the health clinic will ... the three previous large free clinic events this fall in ...
(Date:12/4/2009)... Dec. 4 Pamela Bowen, Chief Information Officer at ... "Chief Innovation Officer" Appy Award for transforming Crescent,s business ... are nominated based on their innovative usage of Salesforce ... of customer success to their sales, marketing, partner, service, ...
Breaking Medicine News(10 mins):Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Free Health Clinic Event Is Not Just for the Sick 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2
... sleep patterns in a type of anesthesia that are ... The anesthetic used in the study, known as ethyl ... more thoroughly investigate ways of treating sleep disorders and ... the studys co-authors and an associate professor of psychology, ...
... Md., April 16, 2008 The U.S. Pharmacopeial ... Program participants. USP is the official standards-setting body ... States. It also sets standards that are widely ... dietary supplements. USPs internship program offers the opportunity ...
... A California Superior Court,today issued a temporary restraining ... Stern and SEIU to cease and desist the,stalking ... officers,directors, and staff of the California Nurses Association/National ... Stern are prohibited from stalking,threatening, or following CNA/NNOC ...
... April 16 Do you know anyone,who,s a ... take personality tests, the cranberry would turn out ... in these little red gems. But the antioxidants,deserve ... ), Often identified in food by their ...
... weekend faced 13.4% lower chance of recovery, study finds , , ... a cardiac arrest are 13.4 percent worse if you are ... according to new research. , Even after taking into account ... age, gender and other illnesses, the lower survival rate remains ...
... around our middle could be making us hungrier, so we ... fat. Dr. Yaiping Yang and his colleagues at the ... Ontario found abdominal fat tissue can reproduce a hormone that ... will change in the way we think about and treat ...
Other Medicine News:Health News:USP announces 2008 summer internship program participants 2Health News:Court Orders Service Union and Its President Andy Stern: Stop Stalking and Harassing Registered Nurse Leaders and Staff of California Nurses Assn/NNOC 2Health News:Court Orders Service Union and Its President Andy Stern: Stop Stalking and Harassing Registered Nurse Leaders and Staff of California Nurses Assn/NNOC 3Health News:Cranberries: The Little Fruit With a Great Big Punch 2Health News:Cranberries: The Little Fruit With a Great Big Punch 3Health News:Your belly fat could be making you hungrier 2
(Date:12/4/2009)... The U.S. Food and Drug Administration (FDA) ... option for the treatment of schizophrenia and manic or ... aged 13-17 years old. ,, The updated Zyprexa ... increased potential for weight gain and hyperlipidemia in adolescents ...
(Date:12/4/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... webcast. Principal investigators will discuss the data presentations ... featured at the 51st American Society of Hematology (ASH) ... a.m. CT/10:00 a.m. ET on Monday, December 7, 2009. ...
(Date:12/4/2009)... Chemistry World recently highlighted a new report ... America ( PhRMA ) that identifies 97 new drugs ... The report found that the 97 products in ... either in human clinical trials or awaiting approval by the ...
Breaking Medicine Technology:FDA Approves Lilly's Zyprexa for Two Adolescent Indications 2FDA Approves Lilly's Zyprexa for Two Adolescent Indications 3FDA Approves Lilly's Zyprexa for Two Adolescent Indications 4FDA Approves Lilly's Zyprexa for Two Adolescent Indications 5FDA Approves Lilly's Zyprexa for Two Adolescent Indications 6FDA Approves Lilly's Zyprexa for Two Adolescent Indications 7Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference 2U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study 5085 1InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study 5085 2Clipa for a Cure 3A New Pink Instant Handbag Hanger Benefits Breast Cancer Research 58508 1Clipa for a Cure 3A New Pink Instant Handbag Hanger Benefits Breast Cancer Research 58508 2BASF Podcast 3A The Chemical Reporter Why Does Fluoride Make Your Teeth Hard 3F 58504 1BASF Podcast 3A The Chemical Reporter Why Does Fluoride Make Your Teeth Hard 3F 58504 2BASF Podcast 3A The Chemical Reporter Why Does Fluoride Make Your Teeth Hard 3F 58504 3
... Survival vs. Interferon-Alpha, COLLEGEVILLE, Pa., Nov. 26 ... WYE ), announced today that the,European Commission has ... with advanced renal cell carcinoma (RCC),who have at ... is the only,approved cancer therapy that specifically inhibits ...
... VioQuest,Pharmaceuticals (OTC Bulletin Board: VQPH) today ... of Lenocta(TM) (sodium stibogluconate), a novel,protein tyrosine ... immune stimulant approved for the treatment of ... cancers. The open-label Phase IIa study is,designed ...
Other Medicine Technology:Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 2Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 3Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 4Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 5Wyeth's TORISEL Receives European Commission Approval for the Treatment of Advanced Kidney Cancer 6VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 2VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 3VioQuest Pharmaceuticals Announces Dosing of First Patient in Phase IIa Solid Tumor Study for Lenocta(TM), a Novel Protein Tyrosine Phosphatase Inhibitor 4
6.5mm diameter handpiece; 75mm handle with grooves for grip; Standard male luer taper fits most cannula hub and female luer taper....
45 degree angled; 5mm from bend to tip; overall length excluding hub 16mm; In Stainless Steel...
3 Piece with .35mm Angled Point, Curved to Left, #8, Side Opening Irrigation, 40mm overall length; in stainless steel; 30cm Long Silicone Tubing with Connector....
Curved to the Left 9# with 30 cm long silicone tubing with connector; 40mm overall length; in stainless steel...
Medicine Products: